Aurisco Pharmaceutical Co Ltd (605116) - Total Assets
Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) holds total assets worth CN¥3.90 Billion CNY (≈ $571.06 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Aurisco Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Aurisco Pharmaceutical Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Aurisco Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Aurisco Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Aurisco Pharmaceutical Co Ltd's total assets of CN¥3.90 Billion consist of 52.8% current assets and 47.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.8% |
| Accounts Receivable | CN¥349.76 Million | 9.0% |
| Inventory | CN¥589.72 Million | 15.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥161.46 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Aurisco Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 605116 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aurisco Pharmaceutical Co Ltd's current assets represent 52.8% of total assets in 2024, a decrease from 74.3% in 2016.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2024, down from 23.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, unchanged from 4.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 15.2% of total assets.
Aurisco Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Aurisco Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Aurisco Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.51 | 2.22 | 6.32 |
| Quick Ratio | 3.15 | 1.33 | 4.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.57 Billion | CN¥761.42 Million | CN¥601.76 Million |
Aurisco Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Aurisco Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 50.6% |
| Total Assets | CN¥3.88 Billion |
| Market Capitalization | $1.34 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Aurisco Pharmaceutical Co Ltd's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aurisco Pharmaceutical Co Ltd's assets grew by 50.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aurisco Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.88 Billion ≈ $567.39 Million |
+50.60% |
| 2023-12-31 | CN¥2.57 Billion ≈ $376.75 Million |
+26.65% |
| 2022-12-31 | CN¥2.03 Billion ≈ $297.47 Million |
+18.09% |
| 2021-12-31 | CN¥1.72 Billion ≈ $251.90 Million |
+12.28% |
| 2020-12-31 | CN¥1.53 Billion ≈ $224.36 Million |
+39.35% |
| 2019-12-31 | CN¥1.10 Billion ≈ $161.00 Million |
+19.50% |
| 2018-12-31 | CN¥920.70 Million ≈ $134.73 Million |
+12.78% |
| 2017-12-31 | CN¥816.38 Million ≈ $119.46 Million |
+4.42% |
| 2016-12-31 | CN¥781.82 Million ≈ $114.41 Million |
-- |
About Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provid… Read more